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Abbreviations: 
ACS acute coronary syndrome 
AMI acute myocardial infarction  
CHF congestive heart failure  
CK creatine kinase 
D2B door to balloon time.  
DP distal protection  
LVEF left ventricular ejection fraction  
IC intracoronary 
IS ischemic size 
IV intravenous 
MACCE major adverse cardiac and cerebral events 
MACE major adverse cardiac events 
MI myocardial infarction.  
MPTP mitochondrial permeability transition pore  
MRI magnetic resonance imaging 
MS myocardial salvage  
MVO microvascular obstruction 
NSTEACS non – ST – segment – elevation acute coronary syndrome  
PostC postconditioning  
PPCI primary percutaneous coronary intervention  
RI reperfusion Injury 
RIC remote ischemic conditioning 
SN sodium nitrate 
STEMI ST – elevation myocardial infarction 
TIMI thrombolytic ischemic myocardial infarction 
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1. Abstract  
Reperfusion therapy with primary percutaneous coronary intervention (PPCI) has become 
the gold standard for treating patients with STEMI. Despite timely reperfusion of the 
affected coronary artery and restoration of blood flow, suboptimal reperfusion in 
myocardial tissue is seen in several patients. Damage of myocardial tissue after PPCI is 
thought to be caused by microvascular obstruction (MVO), no-reflow phenomenon, 
reperfusion injury and others. To optimize myocardial salvage during PPCI, many 
mechanical and pharmacological agents have been developed to address these issues. The 
most common mechanical strategies used during PPCI are: direct stenting, mesh - covered 
stents, self-expanding stents, thrombectomy, distal protection devices, deferred stenting 
and ischemic conditioning. Pharmacological agents such as cyclosporine A, metoprolol, 
abciximab, nitrates, glycogen modulators, nitroprusside, and adenosine can be used as 
adjunctive therapy to achieve better patient outcomes. With door to balloon (D2B) times 
decreasing with still high mortality among STEMI patients, other issues need to be 
addressed such as patient - related delays, and increasing cardioprotection. Combining 
mechanical and pharmacological strategies still remain at an investigational stage and 
needs further research. In the future, evidence based medicine will change clinical 
guidelines on how to treat acute coronary events, which will most likely decrease long-
term side effects, and mortality rates. 
 
 
 
Keywords: suboptimal reperfusion, STEMI. 
 
 
 
 
 
 
 
 
 
2. Sažetak 
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Reperfuzijska terapija s primarnom perkutanom koronarnom intervencijom (PPKI) postala 
je zlatni standard za liječenje bolesnika s STEMI. Unatoč pravovremenoj reperfuziji 
zahvaćene koronarne arterije i obnavljanju protoka krvi, suboptimalni protok krvi u 
miokardijalnom tkivu vidljiv je u brojnim bolesnicima. Oštećenje miokardijalnog tkiva 
nakon PPKI-a je uzrokovano microvaskularnom opstrukcijom (MVO), ne-reflow 
fenomena, reperfuzijskim ozljedama i drugim. Kako bi se optimiziralo spašavanje 
miokarda tijekom PPKI-a, razvijena su mnoga mehanička i farmakološka sredstva za 
rješavanje ovih izazova. Najčešće mehaničke strategije koje se koriste tijekom PPKI-a su: 
direktni stenting, mrežasti stentovi, samo ekspandirajući stentovi, trombektomija, distalni 
zaštitni uređaji, odgođeno stentiranje i ishemijsko kondicioniranje. Farmakološka sredstva 
kao što su ciklosporin A, metoprolol, abciximab, nitrati, modulatori glikogena, nitroprusid, 
adenozin mogu se upotrijebiti kao pomoćna terapija kako bi se postigli bolji ishodi 
bolesnika. U novije vrijeme se brze stize do cath - laba, ali još uvijek je visoka smrtnost 
među pacijentima STEMI-a, zato treba riješiti druga pitanja kao što su kašnjenja vezana uz 
pacijenta i povećanje kardioprotekcije. Kombinacija mehaničkih i farmakoloških strategija 
i dalje ostaje u istražnoj fazi i potrebna je daljnja istraživanja. U budućnosti će ´´medicina 
na temelju dokaza´´ promijeniti kliničke smjernice o liječenju akutnih koronarnih 
događaja, što će najvjerojatnije smanjiti dugoročne nuspojave i smrtnosti. 
 
 
 
Ključne riječi: suboptimalna reperfuzija, STEMI. 
 
 
 
 
 
 
 
 
 
 
3. Introduction  
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In this review, I will consider the causes of suboptimal reperfusion after PPCI, and look at 
the most recent therapeutic advancements. Acute myocardial infarction (AMI) mortality 
has improved the past decades but still represents a major cause of death and heart failure. 
AMI is caused by the rupture of an atherosclerotic plaque, causing intraluminal thrombosis 
resulting in partial or complete occlusion of the affected artery. The restoration of coronary 
blood flow by PPCI does not necessarily lead to restoration of microvascular perfusion at 
the tissue level. This event is associated with increased infarct size (IS), decreased 
ventricular function, and increased mortality. The high occurrence of suboptimal 
reperfusion after PPCI has led to the development of several strategies to protect the 
microcirculation. 
(1)
 
 
4. Mechanisms of myocardial damage 
4.1 Ischemic Injury  
Cardiovascular disease is the leading cause of disability and death in Europe 
(2)
 After 
coronary artery occlusion there is a significant decrease of distal blood flow to the 
cardiomyocytes and ischemia occurs, gradually progressing to necrosis. Typically, the 
necrosis is complete 6 hours after the onset of the occlusion. 
(3)
  Patients presenting with 
ST – elevation myocardial infarction (STEMI) should receive timely reperfusion either by 
thrombolytic therapy or by PCI. Successful reperfusion treatment reduces left – ventricular 
systolic dysfunction, limits IS and reduces the incidence of heart failure after PPCI. 
(2)
 
4.1.1 Choosing the appropriate reperfusion strategy  
Timely reperfusion in the occluded coronary artery is the cornerstone of treatment for 
acute coronary syndromes (ACS). Studies have shown continuous decrease in D2B times 
in the past decades, but there has been little change in-hospital mortality. To improve 
outcomes after ACS it is important to consider other factors such as more effective 
myocardial reperfusion and decreasing reperfusion injury. The American Heart 
Association (AHA) recommend PCI treatment over fibrinolysis if it can be achieved within 
90 minutes after first medical contact. 
(4)
  A study showed that PCI lost its benefit over 
fibrinolysis if the D2B was longer than 121 minutes. 
(5)
 Based on these findings the 
American College of Cardiology/AHA guidelines for STEMI recommend PCI over 
fibrinolysis if it can be achieved between 90 – 120 minutes, with 90 minutes as an aim. On 
the other hand, fibrinolytic therapy should be applied 30 minutes after hospital presentation 
with STEMI, and if it is a non – PCI capable hospital and the transport to a PCI – capable 
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hospital exceeds 120 minutes. Strategies to decrease time to reperfusion is demonstrated in 
Figure 1. 
(4)
 
Figure 1. Patient-related and health-related delays during STEMI.
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As can be seen in figure 1, the total ischemic time is affected by the actions of the patient 
and health system combined. There is a potential for improvement in both patient- and 
health-related delays for treatment of STEMI. The patient related delays can be decreased 
by increasing awareness of STEMI symptoms that would urge patients to seek faster 
medical help. Bypassing the non – PCI hospitals, taking an ECGs before arrival to the 
hospital to achieve a faster response at the cath lab, and increasing PCI capable hospitals 
are other factors to consider.   
4.2. Reperfusion Injury  
Mortality from STEMI remains high and reperfusion injury may be the leading cause of 
this. 
(3)
  Reperfusion injury was first suggested by Jennings et al. in 1960 who reported 
swelling of the cell, disruption of the sarcolemma, myofibril contraction and calcium-
phosphate particles in the mitochondria after reperfusion
.(6,7)
 The benefits of reperfusion 
was further questioned by Braunwald et al. in 1985. who thought it might be a double – 
edged sword. 
(6)
 Recent studies have discovered the pathophysiological pathways for the 
damage caused by RI. After blood flow is restored, there are oxygen tension changes, an 
abrupt increase in intracellular concentration of Ca
2+
, distribution of intracellular Na
+
, and 
pH changes which can induce cardiomyocyte death 
(4) 
Reperfusion injury classically includes: 
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• Myocardial stunning which is a reversible condition when the contractile function 
of the myocytes is impaired. This kind of RI is mainly mediated by calcium overload 
and reactive oxygen species. 
• Reperfusion arrhythmias such as idioventricular rhythm, ventricular tachycardia 
and fibrillation. These conditions are easily treated and often self - terminate.
 (2,8)
 
• Microvascular obstruction (MVO) which can be caused by (i) distal embolization 
of debris; (ii) release of vasoconstrictor and thrombogenic factors; (iii) structural 
collapse of the capillary bed.  
• Lethal reperfusion; defined as injury caused by restoration of blood flow after an 
ischemic episode leading to necrosis of myocytes that were previously only 
reversibly injured during the preceding ischemic episode.
 (9)
  
It has been very hard to prove the existence of myocyte reperfusion injury. The evidence 
has mostly been proven indirectly by applying therapeutic intervention at the onset of 
myocardial reperfusion and decreasing the IS. Based on experimental studies, it is assumed 
that the IS can be reduced up to 50%, suggesting that reperfusion injury may account for 
almost half of the final myocardial infarct size. 
(2)
  
5. Risk factors for suboptimal reperfusion after PPCI 
5.1. Importance of risk factor prevention  
RI in the clinical setting is defined as Thrombolytic Ischemic Myocardial Infarction (TIMI) 
flow grade less than or equal 2, illustrated in Table 1.    
A study from 2003, looked at the impact of suboptimal reperfusion (final TIMI ≤2 flow), 
which included 3,362 patients undergoing PPCI. It showed that patients with a final TIMI 
≤2 after PPCI, were more likely to suffer adverse events and suffer a higher mortality in-
hospital and after 1 year. The study also identified risk factors for final TIMI flow ≤2 
which are summarized in table 2. 
(11) 
Table 1. TIMI Flow Grades 
(10)
 
Grade 0 – Complete occlusion of the affected artery  
Grade 1 – Some perfusion of contrast material beyond the culprit lesion but without 
perfusion distally in the capillary bed 
Grade 2 – Perfusion of the whole infarct affected artery in to the distal bed, with delayed 
flow compared to a normal artery 
Grade 3 – Full perfusion with normal flow 
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Table 2 – Adjusted Odds Ratios of Clinical Variables Associated with the Risk of 
Final TIMI ≤2 Flow (11)  
 
De Luca et al. showed that patients (n=1548) presenting with STEMI undergoing PPCI 
with congestive heart failure, described as Killip class > 1 at admission, had worse final 
TIMI flow grade and poorer long term outcome. 
(12)
 Killip classes I – IV classifies AMI 
severity, where class I shows no evidence of heart failure, and class IV are patients with 
cardiogenic shock.
(10)
 Female patients with anterior MI and multivessel disease were more 
frequent to present with advanced Killip class, and with a higher prevalence of distal 
embolization 
(12)
 Studies have also shown that incomplete ST – segment resolution 
((defined as ≥1 mm ST- segment elevation after PCI) had a correlation with suboptimal 
reperfusion after PPCI.
(10)
 
In addition, patients presenting with unstable hemodynamic factors such as tachycardia 
(>100beats/min), hypotension (<100mmHg) and Killip class >1 were more frequently seen 
in patients with final TIMI ≤2, initially presenting as TIMI ≤1. The angiographic results 
also varied in patients with an end - TIMI flow ≤2 compared to patients with TIMI=3 flow. 
At presentation, the patient in the group TIMI ≤2 were also more likely to present initially 
with TIMI ≤1, left ventricular function (LVEF) < 50%, infarct in the left anterior 
descending artery and with a higher initial percent stenosis of the infarct artery. In this 
study, they used intracoronary arteriolar vasodilators such as nitroprusside, nitroglycerine, 
verapamil and adenosine as adjunctive therapy. These agents were applied in all patients 
with TIMI ≤2 flow.  
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Suboptimal reperfusion after PPCI is recognized as a challenge as the number of STEMI 
patients increases. The incidence of TIMI ≤2 flow occurs in 7, 14% of patients during 
PPCI. This study was important in showing that prevention of final TIMI ≤2 is crucial to 
prevent higher risk of further complications after PPCI. 
(11) 
5.2 Commonly used diagnostic techniques to determine ischemic size 
In the clinical setting, the IS or extent of myocardial necrosis can also be measured by 
biochemical markers and imaging techniques. Biomarkers commonly used are cardiac 
troponins and creatine kinase (CK) myocardial band. Single photon emission computed 
tomography (SPECT) and cardiac magnetic resonance (CMR) are common imaging 
techniques. However, CMR is preferred because it is found to be more accurate in 
estimating necrotic size and it does not cause radiation damage to the patient.
(3)
 Other 
techniques shown to predict of long-term outcome after STEMI are ST – segment 
resolution and TIMI grade.
(13)
 
 
6. Cardiomyocyte conditioning  
6.1 Ischemic Conditioning  
Ischemic conditioning is a term that refers to an endogenous process that protects the heart 
after purposeful interruptions of the blood flow in the infarct – related artery before 
coronary occlusion (preconditioning), after occlusion (postconditioning) or a remote organ 
other than the heart (remote ischemic conditioning). Preconditioning is difficult to execute 
because it implies application of stimuli before the occurrence of an occlusion of the 
coronary artery, which is almost impossible to predict. In this section, I will discuss the 
newest advances on postconditioning and remote ischemic conditioning.  
6.2 Post-conditioning  
To reduce cardiomyocyte death and increase cardio-protection, postconditioning can be 
used to do just this. It is performed after the culprit lesion is opened by PPCI, applying 
cycles of low – pressure balloon inflation before stenting. It has been associated with 
reduction in IS in some studies.
 (4)
 Engstrøm et al. conducted a randomized clinical trial 
(n=1234) where patients were randomized to conventional PCI or to postconditioning 
performed as 30 second occlusions repeated 4 times right after opening of the affected 
artery, and before stent implantation. The study failed to show a reduction in the composite 
outcome of all-cause death and hospitalization for heart failure. IS, MVO and ST – 
segment elevation differences were statistically insignificant in the two different groups.
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(14)
 Recently, Eitel et al. conducted a randomized study to evaluate if the combination of 
remote ischemic conditioning (RIC) and postconditioning (PostC)  (n=232) was more 
effective in myocardial salvage compared to  PostC (+PCI) (n=232) and conventional PCI 
(control group, n=232). Peak CK values and ST – segment resolution were lowest in the 
combined group. The main finding in this trial was that RIC + PostC vs. PostC alone and 
conventional PCI was better in increasing myocardial salvage, that they have additive 
cardioprotective effects. PostC failed to show improved myocardial salvage when 
compared to the control group.
 (15) 
 
6.3 Remote ischemic conditioning  
Ischemic preconditioning is a cytoprotective strategy used to counter myocardial ischemia. 
(16)
 It has an effect like post-conditioning on the heart muscle by releasing cardioprotective 
circulating factors.
 (17)
 Applying repetitive cycles of ischemia-reperfusion in a tissue distant 
to the heart, has been associated with decreased peak troponin I levels, and greater 
myocardial salvage.
 (4)
  
In one study, patients were exposed to remote ischemic conditioning vs no conditioning 
where remote ischemic conditioning (RIC) was performed by using a blood pressure cuff 
to inflate and deflate the upper arm in the ambulance before reaching the hospital. 4 cycles 
of 5-minute inflation, followed by 5 minutes of deflation were applied to the upper arm 
using a sphygmomanometer. It was associated with lower major adverse cardiac events 
(MACE) and mortality.
 (4)
 The randomized ongoing RIC-STEMI trial is assessing if short 
cycles of ischemia-reperfusion to a limb will reduce the final IS before undergoing 
PPCI.
(16)
 The beneficial effects of RIC have to be confirmed in bigger studies in order to be 
implemented in future guidelines as an adjunct to PPCI.  
 
7. The no – reflow phenomenon  
When a coronary artery is relived from severe stenosis by PCI and blood flow to the 
ischemic tissue remains impeded, is known as no reflow phenomenon. PPCI usually opens 
the occluded epicardial artery in 95% of cases, however, suboptimal tissue reperfusion 
often remains due to MVO leading to increased IS, remodeling of the left ventricle, and 
higher endpoint percentage of death. Trying to explain the no- reflow phenomenon and 
MVO after PPCI it is believed that distal embolization of thrombotic debris is crucial in 
development of this condition and subsequent clinical consequences. 
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Figure 2. Various 
mechanisms implicated in 
the genesis of the no-reflow 
phenomenon. 
(18)
 
As seen in figure 2, the no-
reflow process is influenced 
both by the ischemic and 
reperfusion period. 
(18)
  
Despite having a patent vessel and no coronary dissection, spasm nor distal macroembolus 
after PPCI there is a distal filling defect distal to the site of PCI. It has been suggested to be 
connected to microvascular dysfunction.   
The incidence of no – reflow has varied a lot depending on which imaging technique was 
used. Some studies have shown 12 % to 25 %, while in the PAMI and CADILLAC trials 
the incidence was significantly lower, only 4 % to 7 %. Using myocardial contrast 
echocardiography has shown 34% to 39%. Factors that have been observed to affect the no 
– reflow are Killip class, Q wave numbers, the motion of the ventricular wall on 
echocardiogram, and initial TIMI flow grade 0 on the coronary angiogram. Another 
important predictor is the time it takes to reperfusion from symptom onset. 
(10)
 The no – 
reflow phenomenon strongly predicts long – term cardiac complications after AMI.(19) 
Several factors are probably connected to the no-reflow phenomenon. Distal embolization 
of thrombotic material, damage to the microvascular bed, necrosis and stunning of the 
myocardium after reperfusion injury. 
(10) 
In the next sections, I will discuss mechanical and 
pharmacological therapeutic strategies to counter suboptimal reperfusion.  
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8. Mechanical strategies to enhance myocardial salvage during PPCI 
Mechanical strategies such as direct stenting, mesh – covered stents, self – expanding 
stents, deferred stenting, thrombectomy and distal protection devices promote myocardial 
salvage by reducing distal embolization.
 (3) 
 
8.1 Direct Stenting 
 Direct stenting is stenting without balloon pre-dilatation. A cohort study published in 2001 
showed reduction of angiographic no – reflow (5.5% vs 12.0%; p=0.04), and reduced 
mortality (1.0% vs 8.0%) in the group undergoing PCI with direct stenting compared to 
balloon dilatation with stent implant, respectively. Another study showed reduction in 
TIMI endpoint (11.7% vs 26.9 %; p=0.01) and ST – segment resolution (79.8% vs 61.9%; 
p =0.01) among patients randomized to direct stenting compared to stent implantation after 
balloon predilation. In a bigger study called Harmonizing Outcomes with 
Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) they 
showed a better ST – segment resolution with direct stenting (n=698) compared to balloon 
angioplasty with stent implant (n= 1,830). Mortality (1.6% vs. 3.8%; p=0.01) and stroke 
(0.3% vs 1.1%; p=0.049) were also reduced among patients undergoing direct stenting. 
From the EUROTRANSFER registry, data on 1,419 patients who underwent PPCI after 
AMI where direct stenting (n=276), and conventional stenting (n=1143) were compared. 
Final TIMI grade 3 (94.9% vs 91.5%; p=0.020) and reduced risk of no – reflow 
phenomena (3.4% vs 1.4%; p=0.035). The mortality at 1 year was lower in the direct 
compared to the conventional stenting group (6.5% vs. 2.9%, p = 0.047).  
Direct- compared with conventional stenting resulted in significantly greater rates of 
postprocedural TIMI grade 3 flow (conventional vs. direct stenting: 91.5% vs. 94.9%, 
adjusted odds ratio (OR) 2.09 (1.13-3.89), P = 0.020), and lower risk of no-reflow (3.4% 
vs. 1.4%, adjusted OR 0.31 (0.10-0.92), P = 0.035). The rates for ST-segment resolution 
>50% after PCI were higher in patients treated with direct stenting technique (76.3% vs. 
86.2%, adjusted OR 1.64 (1.10-2.46), P = 0.016). A significant reduction in 1-year 
mortality in patients from the direct stenting group compared with the conventional 
stenting group, even after adjustment for propensity score was observed (6.5% vs. 2.9%, 
adjusted OR 0.45 (0.21-0.99), P = 0.047). (20) 
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8.2 Mesh – covered stents 
Mesh covered stents trap distal embolic debris at the culprit lesion in patients with STEMI. 
In the MASTER (Safety and Efficacy Study of MGuard Stent After a Heart Attack) trial 
they randomized patients to a MGuard stent, or to a bare metal or drug – eluting stent 
within 12 hours of presentation with STEMI. It showed that ST - segment resolution (70% 
vs 57.8% vs 44.7%, respectively) and TIMI flow grade 3 were achieved more frequently in 
the patients receiving the MGuard stent (91.7% vs 82.9%; p=0.006). However, at 1 year 
the incidence of MACE were increased in the mesh covered stent group. (9.1% vs. 3.3%; 
p=0.02) but mortality at 1 year remained lower in the MGuard stent group (1.0% vs 3.3%; 
p=0.09). The trial concluded that the MGuard stent does prevent distal emboli in patients 
with STEMI with a high thrombus burden. Nonetheless, looking at these results, the use of 
MGuard stents in STEMI patients remains limited and further investigations are needed. 
(20) 
 
8.3 Self – expanding stents 
Underestimation of the vessel size is a well-known challenge in PCI. Self – expanding 
stents can adjust to the vessel itself, by gradually growing, deploying at a lower pressure 
compared to direct stents. This method may cause less local trauma and plaque disruption 
leading to less distal embolization of thrombotic content. Imaging techniques 
(angiography, intravascular ultrasound) after deployment of these stents showed that they 
expanded to the same degree as the epicardial vasodilation and appeared completely 
connected to the vessel wall. However, concerns have been voiced concerning optimal 
stent/vessel ratio, over – expansion after stent deployment predisposing for plaque 
prolapse, and stopping of stent expansion in calcified lesions. The experience with self – 
expanding stents remain limited in the PPCI setting, and further investigations are needed 
to conclude if they reduce distal embolizations and MVO.
(20) 
 
8.4 Deferred stenting 
Deferred stenting is a two -step intervention with balloon angioplasty performed first, 
followed by stent implantation hours (to days) after the initial procedure. 
(20)
 Carrick et al. 
assessed if deferred stenting reduces no – reflow and save myocardial tissue in STEMI 
during PPCI. 101 patients with STEMI and ≥ 1 risk factors for no - reflow were 
randomized to deferred stenting (n=52) or to conventional (immediate) stenting (n=49). 
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The median time of deferral was 9 hours. The CMR imaging results at 6 months after the 
procedure showed reduced no-reflow and increased myocardial salvage in the deferred 
stenting group during PPCI. Many randomized trials are being performed to further 
determine the benefits of deferred stenting vs. immediate stenting. 
(21)
 
8.5 Cardioprotection with mechanical and aspiration thrombectomy 
Thrombus removal by thrombectomy has been used in PPCI to decrease the likelihood of 
distal embolization in occluded coronary arteries. Using either a mechanical or aspiration 
thrombectomy method, where it has been assessed in many studies to see if it is superior to 
conventional PCI, in decreasing the chance of distal MVO, and in increasing myocardial 
salvage. Thrombus aspiration has been studied in many studies to see if it could reduce 
both MVO and decrease final myocardial IS. Using this approach has shown mixed results 
during the past years. 
(1)
 
In the randomized TAPAS (the Thrombus Aspiration during Percutaneous coronary 
intervention in Acute myocardial infarction Study) trial, 1071 patients were randomly 
divided into the thrombus-aspiration group or the conventional- PCI group before 
undergoing coronary angiography. If there was histopathological evidence of thrombotic 
material after aspiration it would be considered successful. The results of the study showed 
that aspiration thrombectomy during PPCI had beneficial effects on myocardial reperfusion 
compared to conventional PCI alone, regardless of clinical and angiographic characteristics 
at baseline. The results from this study agree with the findings in the randomized EXPIRA 
(Impact of Thrombectomy With EXPort Catheter in Infarct-Related Artery During Primary 
Percutaneous Coronary Intervention on Cardiac Death) trial
. (1)
 
The EXPIRA study randomized 175 patients with STEMI undergoing PPCI to thrombus 
aspiration (n=88) or conventional PCI (n=87). Clinical follow – up was made at 9 and 24 
months in patients to assess the occurrence of MACEs, such as nonlethal reinfarction, 
target vessel revascularization and cardiac death. The main finding in EXPIRA was that 
patients that had undergone aspiration thrombectomy had a lower incidence of MACEs at 
2-year flow – up compared to just standard PCI. Occurrence of MACEs was much higher 
in the group not receiving thrombectomy (13.6% vs 4.5%, p=0.038).
 (13)
 However, in a 
prospective controlled pilot study, results showed no effect on left ventricular function.
 (22)
 
 
Recent studies in the field of manual thrombectomy during PPCI has not shown beneficial 
evidence.
 (20)
 Jolly et al. randomly assigned 10,732 patients with STEMI to manual 
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thrombectomy during PPCI versus standard PCI. The primary outcome was a combination 
of cardiovascular deaths, MIs reoccurring, cardiogenic shock or NYHA (New York Heart 
Association) class IV heart failure within 180 days. It occurred in 347 out of 5033 (6.9%) 
in the thrombectomy group vs 7.0 % (p=0.86) in the alone- PCI group. The secondary 
outcome, stroke within 30 days, occurred in 0.3% vs 0.7% in the conventional vs manual 
thrombectomy group respectively. The randomized study clearly showed the lack of 
efficacy of manual thrombotic aspiration and the association with increased risk of 
neurological complications.
(23)
 In addition, the INFUSE – AMI randomized trial failed to 
show decreased IS at 30 days after PPCI using manual thrombectomy. 
(24)
 
 
8.6 Distal protection devices 
Proximal or distal occluders, distal filters and thrombus extraction devices can be used to 
decrease the embolic burden at the culprit lesion in patients undergoing PPCI. The SAFER 
(Saphenous vein graft angioplasty Free of Emboli Randomized) trial showed that distal 
protection devices protect distal embolization and improve clinical outcome in bypass graft 
vessels. However, several trials using these devices have been unsatisfactory.
(20) 
In the 
DEDICATION (The Drug Elution and Distal Protection in ST – Elevation Myocardial 
Infarction) trial patients presenting with STEMI within 12h of symptom onset were 
randomized to PCI with (n=312) or without (n=312) distal protection, using a filterwire 
system. The results showed that a routine use of distal protection with a filterwire system 
during PPCI was not recommended. It did not appear to decrease infarct size nor reduce 
major adverse cardiac and cerebral events (MACCE).
(25)
 
 
In one study, Doppler guidewire was used to detect embolic particles during PCI in 
patients with AMI where visible debris has been retrieved in 73% of the patients during 
PPCI. The study also assessed if the embolic particles would be reduced if using a distal 
protection (DP) device. The conclusion was that the DP device did effectively prevent 
embolization in all patients in the DP – group. (26) However, it remains unknown if the DP 
device can reduce the embolic burden in the clinical setting. In the EMERALD (Enhanced 
Myocardial efficacy and recovery by aspiration if liberated debris) trial they discovered 
that embolic debris is liberated and may be retrieved in several patients by using the 
GuardWire during PPCI, DP from emboli did not improve microvascular flow, IS was not 
15 
 
improved nor reduce mortality. Therefore, they concluded that the routine use of 
GuardWire is not recommended. 
(27)
  
9. Pharmacological strategies in suboptimal reperfusion during PPCI 
Pharmacological therapeutic strategies are used to reduce IS by reduction of RI. There has 
been done many studies on possible pharmacological therapies to prevent RI. Many studies 
have not been able to prove benefits of the drugs tested. In this section I will mention the 
most relevant pharmacological agents proven to reduce RI. 
 
9.1 Cyclosporine A 
Some studies have shown that mitochondrial permeability transition pore (MPTP) is an 
important element of reperfusion injury. MPTP is a downstream component in the 
signaling pathway involved in reperfusion injury and is becoming and target for 
pharmacotherapy.  
Cyclosporine A is a drug that inhibits MPTP channel opening, the inhibition of MTPT is 
an event also observed with postconditioning. 
(28)
 A small trial (n=58) investigated if 
intravenous (IV) bolus of 2.5mg/kg cyclosporine administration right before undergoing 
PCI would limit the IS at the time of a MI vs normal saline administration. The data 
gathered showed that CK levels were reduced in the cyclosporine A group compared to the 
control group (p=0.04). Troponin levels were similar whereas the IS was lowered on day 5 
using CMR in the group receiving cyclosporine A with a median of 37g vs 46g in the 
control group (p=0.04). 
(29) 
Despite the small study, these results showed promising 
therapeutic advances in decreasing IS using cyclosporine A during PPCI. Despite these 
results, this study was small, and a meta – analysis was done on 20 experimental studies 
observing pig hearts that showed heterogenic results raising concern about the 
cardioprotective effects of cyclosporine A in humans. 
(28) 
 
9.2 Metoprolol 
Ibanez et al. investigated if IV metoprolol administration immediately before PPCI 
decreases IS. Patients (n=270) were randomized to receive IV metoprolol (n=131) or not 
(n=139) before reperfusion of the affected artery(ies). The effect of beta blockers has been 
studied thoroughly before the era of PCI and lacked promising results. However, this trial 
was aiming to test the infarct limiting effect of metoprolol during PPCI. Current clinical 
guidelines do not include the application of metoprolol during standardized PPCI, 
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however, it can be applied if deemed appropriate. Patient qualified for enrollment were 18 
to 80 years old, experienced STEMI for > 30 minutes and had a ST – segment elevation 
≥2mm with ≤6 hours of symptom onset to reperfusion. Exclusion criteria were patients 
actively using beta – blockers, Killip class III or IV AMI, systolic blood pressure < 
120mmHg, atrioventricular block type II or III or bradycardia.
 
The patients were 
randomized to receive maximum of 5mg boluses of metoprolol tartrate 2 minutes apart. 
Otherwise, patients were treated in accordance to current guidelines. In addition, all 
patients received oral metoprolol tartrate during hospitalization in line with clinical 
guidelines. The mean infarct size measured by CMR was smaller after IV metoprolol 
(25.6g ± 15.3g) compared to the control group (32.0g ± 22.2g, p=0.012). The LVEF was 
improved and MACE was reduced in the drug receiving group compared to conventional 
PCI (7.1% vs 12.3%, respectively, p=0.21). Patients receiving IV metoprolol immediately 
before PCI in patients with anterior Killip class ≤2 AMI reduced IS and increased LVEF 
during the first day after STEMI. 
(30) 
 
9.3 Glycoprotein IIb/IIIa platelet receptor inhibitors 
Abciximab:  The INFUSE – AMI randomized trial, used two strategies during PPCI that 
were previously proposed to benefit patient outcome after PPCI. They determined whether 
intracoronary bolus of abciximab vs no abciximab, and manual aspiration thrombectomy 
vs no thrombectomy would decrease distal emboli and improve patient outcome after 
reperfusion therapy. All patients also received bivalirudin anticoagulation undergoing 
PPCI. The results of the study showed that patients randomized to intracoronary (IC) 
abciximab compared to no drug had reduction in IS at 30 days measured by CMR (median 
15.1% vs 17.9%, respectively, p=0.03). Patients undergoing PPCI with aspiration 
thrombectomy showed no significant difference (median, 17.0% vs 17.3%, p=0.51). They 
concluded that application of abciximab decreased IS whereas manual aspiration 
thrombectomy did not. (24) IC vs IV bolus abciximab was compared by Thiele et al. The 
randomized study showed that IC (n=77) vs IV (n=77) administration of abciximab during 
PPCI reduced the median IS (15.1% vs 23.4%, respectively) and MVO. The TIMI flow 
grade was the same in the two groups. 
(31)
 However, not all trials have been positive
. (32)
 
Tirofiban: 
Recent studies have researched this drug which disappointing results. Song et al. applied a 
high-dose of tirofiban during PPCI to assess IS vs conventional PCI. It did not show long - 
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term benefits. In a study, where tirofiban was administered (vs. placebo) before reaching 
the hospital also lacked promising results. 
(33)
 
 
9.4 Glucose modulators 
The double blind IMMEDIATE (The Immediate Myocardial Metabolic Enhancement 
During Initial Assessment and Treatment in Emergency Care) trial randomized patients to 
administration of glucose, insulin and potassium (GIK) vs placebo during transfer to the 
hospital. This was done in patients suspected of ACS. They assessed the progression of 
ACS to MI within 24 hours by ECG and biomarkers. There was no difference in 
progression to MI between patients in the GIK – receiving group (n=200, 48.7%) vs 
placebo (n=242, 52.6%), however, in the subgroup of patients presenting with STEMI, the 
GIK – receiving group had reduced IS measured by CMR. (34) However, a meta – analysis 
that involved more than 28 000 patients, did not find any significant benefits with GIK 
therapy. 
(35)
 Further studies are needed to assess the use of GIK as pretreatment in the out-
of-hospital setting for patients with ACS.  
 
9.5 Adenosine and Nitroprusside  
In the multicenter REOPEN-AMI study (intracoronary nitroprusside versus adenosine in 
AMI) assessed if nitroprusside or adenosine administered after thrombus aspiration would 
improve patient outcome. The patients were randomly assigned to 3 different groups, to 
receive i) adenosine (n=80), ii) nitroprusside (n=80) and iii) saline (n=80). Positive results 
of the study were based on ST - segment resolution > 70%, where there was 71% 
resolution in group i), 54% in group ii) and 51% in group iii). Furthermore, at 30 days, the 
angiographic MVO was significantly reduced in the adenosine group compared to the 
nitroprusside and controlled group (18% vs. 24% vs. 30% respectively, p=0.06 and p=0.37, 
respectively, vs. saline.) In addition, MACE was lower in group 1 and 2, compared to 
group 3. (10%, vs. 14% vs. 20%, respectively, p=0.08, and p= 0.29 vs. saline). This study 
showed that patients undergoing thrombus aspiration with IC injection of adenosine had 
significant improvement of MVO, as assessed by ST - segment resolution. Another study 
conducted by Parikh et al., showed that combination therapy with adenosine and 
nitroprusside improved coronary flow and decreased MACE if compared to adenosine 
alone during PPCI. 
(35, 36, 37)
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Robert A. Kloner reviewed trials on the cardioprotective effects of adenosine during PPCI. 
The Acute Myocardial Infarction Study of Adenosine (AMISTAD) 1 and 2, showed that 
adenosine reduced anterior wall MI after a 3 - hour long administration of high dose IV 
infusion that was introduced at the time of PPCI.  However, the drug did not significantly 
decrease the total congestive heart failure (CHF) in AMISTAD 2. A different sub-study 
showed contrary results, where in fact, adenosine did reduce overall CHF. In a prospective, 
double blind, single center trial, they could not find evidence supporting a high dose IC 
injection of adenosine to increase myocardial salvage nor decrease MVO. However, this 
study was limited by the small population group, and it was only done in one center. 
(33, 38)
 
The Safety and Effectiveness of Nitroprusside in Preventing No-Reflow During 
Percutaneous Coronary Intervention: A Systematic Review study evaluated the clinical 
proficiency of sodium nitroprusside in preventing the no-reflow phenomenon. This meta - 
analysis concluded that TIMI flow was improved and incidence of no-reflow reduced.   
The use of sodium nitroprusside is still controversial, and no standardized clinical 
guidelines exist. 
(39)
 
 
9.6 Sodium nitrite and nitric oxide 
Sodium nitrate is an arteriolar vasodilator, inhibits platelets and has anti-inflammatory 
abilities. The NIAMI (intravenous sodium nitrite (SN) in acute ST-elevation myocardial 
infarction) trial randomized 229 patients with STEMI to either intravenous SN or to 
placebo for 5 minutes before PPCI. CMR was performed at 6-8 days and 6 months later to 
assess IS. The trial showed no benefits of intravenous SN concerning reduced IS. 
(40)
 Nitric 
oxide inhalation in patients undergoing PPCI during STEMI, was evaluated in the Nitric 
Oxide for inflation to reduce repercussion injury in acute STEMI (NOMI) trial, which 
showed no increased myocardial salvage measured by CMR. 
(28)
  
 
10. Negative studies  
There has been mentioned several clinical studies that showed no significant clinical 
improvement earlier in this review. In addition to these, some disappointing trials include: 
 i) caldaret (vasodilator), ii) delcasertib (protein kinase inhibitor, PROTECTION-AMI 
trial), iii) erythropoietin (REVEAL trial) and iv) eniporide (Na+/H+ exchange inhibitor, 
ESCAMI trial. Limited results in i) BQ - 123 (endothelium receptor inhibitor), nicoranidil 
(combined nitrate and potassium - ATP channel agonist) and iii) Hyperbaric oxygen 
administration (AMIHOT trial). 
(3, 33)
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11. Conclusions 
In the past decade, several advancements in the treatment of STEMI have evolved. Despite 
of the life - saving properties of PPCI and further reductions in D2B times, it has not 
changed mortality rates a lot. Currently there is no strategy that is optimal for the treatment 
of STEMI. To improve patient outcomes, these results suggest that additional factors must 
be addressed. Suboptimal reperfusion after PPCI is caused by several factors such as MVO 
and reperfusion injury. However, increasing knowledge has enabled us to target these 
challenges more efficiently. A combination of mechanical strategies and pharmacological 
agents discussed above, may optimize treatment by improving myocardial final TIMI 
grade, decreasing MACE and mortality. Using adjunctive therapy with PPCI, might be the 
best therapeutic option for patients to further improve patient outcome during PPCI. 
Ongoing studies around the world will help answer some of these questions and hopefully 
revolutionize the treatment of STEMI.  
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